JP2023531944A5 - - Google Patents

Info

Publication number
JP2023531944A5
JP2023531944A5 JP2022579109A JP2022579109A JP2023531944A5 JP 2023531944 A5 JP2023531944 A5 JP 2023531944A5 JP 2022579109 A JP2022579109 A JP 2022579109A JP 2022579109 A JP2022579109 A JP 2022579109A JP 2023531944 A5 JP2023531944 A5 JP 2023531944A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
inhibitor
tlr7
tnfα inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2022579109A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023531944A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/038170 external-priority patent/WO2021262561A1/en
Publication of JP2023531944A publication Critical patent/JP2023531944A/ja
Publication of JP2023531944A5 publication Critical patent/JP2023531944A5/ja
Withdrawn legal-status Critical Current

Links

JP2022579109A 2020-06-22 2021-06-21 関節リウマチの治療 Withdrawn JP2023531944A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN202011026256 2020-06-22
IN202011026256 2020-06-22
PCT/US2021/038170 WO2021262561A1 (en) 2020-06-22 2021-06-21 Treating rheumatoid arthritis

Publications (2)

Publication Number Publication Date
JP2023531944A JP2023531944A (ja) 2023-07-26
JP2023531944A5 true JP2023531944A5 (https=) 2024-04-30

Family

ID=76959071

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022579109A Withdrawn JP2023531944A (ja) 2020-06-22 2021-06-21 関節リウマチの治療

Country Status (11)

Country Link
US (1) US20230310409A1 (https=)
EP (1) EP4168049A1 (https=)
JP (1) JP2023531944A (https=)
KR (1) KR20230027212A (https=)
CN (1) CN115768479A (https=)
AU (1) AU2021296150A1 (https=)
BR (1) BR112022025920A2 (https=)
CA (1) CA3183306A1 (https=)
IL (1) IL299147A (https=)
MX (1) MX2022015146A (https=)
WO (1) WO2021262561A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230171469A (ko) 2021-04-16 2023-12-20 길리애드 사이언시즈, 인코포레이티드 티에노피롤 화합물
EP4398989A1 (en) 2021-09-10 2024-07-17 Gilead Sciences, Inc. Thienopyrrole compounds
TW202535949A (zh) 2023-12-20 2025-09-16 美商必治妥美雅史谷比公司 靶向IL-18受體β(IL-18RB)之抗體及相關方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016356780A1 (en) * 2015-11-19 2018-06-28 Bristol-Myers Squibb Company Antibodies against glucocorticoid-induced tumor necrosis factor receptor (GITR) and uses thereof
US10071079B2 (en) * 2016-06-29 2018-09-11 Bristol-Myers Squibb Company [1,2,4]triazolo[1,5-a]pyridinyl substituted indole compounds
EP3853252A1 (en) * 2018-09-18 2021-07-28 Merrimack Pharmaceuticals, Inc. Anti-tnfr2 antibodies and uses thereof

Similar Documents

Publication Publication Date Title
JP2023531944A5 (https=)
US20110256130A1 (en) Methods of treating inflammatory disorders
JP2019147801A5 (https=)
JP2022514255A5 (https=)
JP2021525248A5 (https=)
JP2024029009A5 (https=)
JP2023505492A5 (https=)
JP2011526244A (ja) 炎症の処置方法
JP2023501375A5 (https=)
RU2017107501A (ru) Применение антагонистов il-17 для торможения прогрессирования структурных повреждений у пациентов с псориатическим артритом
JP2023540795A5 (https=)
JP2019511550A5 (https=)
JP2022544624A5 (https=)
JP2024504260A5 (https=)
WO2019197477A1 (en) C-type natriuretic peptide engrafted antibodies
CN104087593A (zh) 一种抗WSSV自噬相关基因Cq-Atg8及其制备方法与应用
JP6918005B2 (ja) 細胞内抗原に対して向けられた単一ドメイン抗体
KR20210003787A (ko) 심방 나트륨이뇨 펩티드 이식된 항체
RU2018129077A (ru) Стабильная фармацевтическая композиция
JP2022500389A5 (https=)
Gosavi et al. Comparative study on treatment of rheumatoid arthritis
KR20210003788A (ko) 뇌 나트륨이뇨 펩티드 이식된 항체
JP2022534794A5 (https=)
JP2022529266A5 (https=)
JP2023527200A5 (https=)